Next Article in Journal / Special Issue
Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination
Previous Article in Journal
Post Approval Human Papillomavirus Vaccine Uptake Is Higher in Minorities Compared to Whites in Girls Presenting for Well-Child Care
Previous Article in Special Issue
Vector Design for Improved DNA Vaccine Efficacy, Safety and Production
Vaccines 2013, 1(3), 262-277; doi:10.3390/vaccines1030262
Article

Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation

1,* , 2
, 1
, 3
, 3
, 4
, 1
, 1
, 1,†
, 2
 and 5
Received: 31 May 2013; in revised form: 8 July 2013 / Accepted: 10 July 2013 / Published: 18 July 2013
(This article belongs to the Special Issue DNA Vaccines)
View Full-Text   |   Download PDF [512 KB, uploaded 18 July 2013]   |   Browse Figures
Abstract: Lassa virus (LASV) causes a severe, often fatal, hemorrhagic fever endemic to West Africa. Presently, there are no FDA-licensed medical countermeasures for this disease. In a pilot study, we constructed a DNA vaccine (pLASV-GPC) that expressed the LASV glycoprotein precursor gene (GPC). This plasmid was used to vaccinate guinea pigs (GPs) using intramuscular electroporation as the delivery platform. Vaccinated GPs were protected from lethal infection (5/6) with LASV compared to the controls. However, vaccinated GPs experienced transient viremia after challenge, although lower than the mock-vaccinated controls. In a follow-on study, we developed a new device that allowed for both the vaccine and electroporation pulse to be delivered to the dermis. We also codon-optimized the GPC sequence of the vaccine to enhance expression in GPs. Together, these innovations resulted in enhanced efficacy of the vaccine. Unlike the pilot study where neutralizing titers were not detected until after virus challenge, modest neutralizing titers were detected in guinea pigs before challenge, with escalating titers detected after challenge. The vaccinated GPs were never ill and were not viremic at any timepoint. The combination of the codon-optimized vaccine and dermal electroporation delivery is a worthy candidate for further development.
Keywords: Lassa fever; Lassa virus; arenavirus; guinea pigs; dermal electroporation; vaccination; vaccine Lassa fever; Lassa virus; arenavirus; guinea pigs; dermal electroporation; vaccination; vaccine
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Cashman, K.A.; Broderick, K.E.; Wilkinson, E.R.; Shaia, C.I.; Bell, T.M.; Shurtleff, A.C.; Spik, K.W.; Badger, C.V.; Guttieri, M.C.; Sardesai, N.Y.; Schmaljohn, C.S. Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation. Vaccines 2013, 1, 262-277.

AMA Style

Cashman KA, Broderick KE, Wilkinson ER, Shaia CI, Bell TM, Shurtleff AC, Spik KW, Badger CV, Guttieri MC, Sardesai NY, Schmaljohn CS. Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation. Vaccines. 2013; 1(3):262-277.

Chicago/Turabian Style

Cashman, Kathleen A.; Broderick, Kate E.; Wilkinson, Eric R.; Shaia, Carl I.; Bell, Todd M.; Shurtleff, Amy C.; Spik, Kristin W.; Badger, Catherine V.; Guttieri, Mary C.; Sardesai, Niranjan Y.; Schmaljohn, Connie S. 2013. "Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation." Vaccines 1, no. 3: 262-277.


Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert